SECURITIES AND EXCHANGE COMMISSION

FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: **2023-02-16** | Period of Report: **2023-02-14** SEC Accession No. 0000899243-23-005299

(HTML Version on secdatabase.com)

REPORTING OWNER

Euh Hosun

CIK:1953684

Type: 4 | Act: 34 | File No.: 001-41390 | Film No.: 23639976

Mailing Address 10900 NE 4TH STREET, SUITE 2300 BELLEVUE WA 98004

ISSUER

Bellevue Life Sciences Acquisition Corp.

CIK:1840425| IRS No.: 845052822 | State of Incorp.:DE | Fiscal Year End: 1231 SIC: 6770 Blank checks

Mailing Address 10900 NE 4TH STREET, SUITE 2300 BELLEVUE WA 98004 Business Address 10900 NE 4TH STREET, SUITE 2300 BELLEVUE WA 98004 425-635-7700

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL											
OMB Number:	3235-0287										
Expires:	02/28/2011										
Estimated average b	urden										
nours per response	0.5										

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Euh Hosun			2. Issuer Name and Ticker or Trading Symbol Bellevue Life Sciences Acquisition Corp. [BLAC]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/14/2023	below) below)				
10900 NE 4TH S	TREET, SUITE	2300						
(Street) BELLEVUE, WA 98004			4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing (Check applicable line) X Form Filed by One Reporting Person Form Filed by More than One Reporting Person				
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/ Day/Year)	Deemed			4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Securities Beneficially Owned	Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v		(A) or (D)	Price		,	
Common Stock	02/14/2023		<u>A</u>		20,000	A	\$ 0	20,000 (1)	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/ Day/Year)	3A. Deemed Execution Date, if any (Month/ Day/ Year)	4. Transa Code (Instr. 8		of Deriv	vative irities ired r osed)	6. Date Exer and Expiratio (Month/Day/	on Date	Amount Securitie Underlyi Derivativ	Underlying Derivative Security (Instr. 3		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Represents the shares transferred by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer, to Mr. Euh for his board service.

Signatures

/s/ Hosun Euh

02/16/2023

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.